Current Evidence for the Use of Aspirin in Patients with Atrial Fibrillation and a CHA2DS2-Vasc=1
Journal Title: Clinical Cardiology and Cardiovascular Medicine - Year 2019, Vol 3, Issue 1
Abstract
Aspirin was once the mainstay of stroke prevention in patients with atrial fibrillation. Its popularity was based on the results of the SPAF and PATAF trials, which showed the low risks of this therapy and the many benefits it had to offer in terms of embolic complications prevention. Nevertheless, aspirin has lost popularity in atrial fibrillation since the CHADS, CHA2DS2-VASc and HASBLED scoring systems were first introduced. These scoring systems showed a different perspective, which highlighted that thromboembolic risk varied among individuals and that a generalization on antiplatelet therapy for atrial fibrillation was not effective. These caveats gave support to additional treatments based on anticoagulation, including warfarin and direct oral anticoagulants. These treatments gained popularity based on the superiority over warfarin, first described on the BAFTA trial, which nominated the warfarin as the standard of care for atrial fibrillation thromboembolic prevention. Since then, direct anticoagulation therapies have gained popularity based on the results of the ARISTOTLE (apixaban), RE-LY (dabigatran), ROCKET-AF (rivaroxaban), ENGAGE TIMI 48 AF (edoxaban) trials. However, the CHA2DS2-VASc score was generous with aspirin, since it opened a possible recommendation for low CHA2DS2-VASc scores (0-1). This comprehensive literature review is intended to discuss the arguments behind this last statement and to show the available evidence in favor of and against aspirin for non-valvular atrial fibrillation in low thromboembolic risk patients.
Authors and Affiliations
Juan Simon Rico-Mesa
Keywords
Related Articles
- EP ID EP606079
- DOI 10.33805/2639.6807.117
- Views 53
- Downloads 0
Endothelial Cells Strengthening: Improving Functions in Management of Acute Coronary Syndrome (A Double Blind Randomized Interventional Control Trial)
Objective: Endothelial dysfunction/injury is the main reason for Acute Coronary Syndrome (ACS). Current therapy includes antiplatelet, lipid lowering and thrombus removal by drugs/ intervention. Endothelial strengthening...
Prevalence of Hyperuricemia and its Association with Other Cardiovascular Risk Factors in Adult Yemeni People of Sana’a City
Objective: Hyperuricemia is a metabolic problem that has become increasingly common worldwide over the past several decades. Its prevalence is increased in both advanced and developing countries including Yemen. The aim...
Six-Minute Walk Test in Pediatric Cardiac Patients
Background: The 6MWT (6MWT) is a self-paced walking test generally used to assess the functional capacity in people with chronic conditions the main outcome is the distance that a person can walk in 6 minutes. The 6 MWT...
Healing Myocarditis from a Hypertrophied Heart with Multifocal Fibrosis Mimicking Cardiomyopathy
We report the case of an 18 year old man who unexpectedly died of healing myocarditis. His heart was hypertrophied with multifocal fibrosis which can be a common histological feature of primary and secondary cardiomyopat...
The Impact of Cytochrome P450 2C19 Polymorphism on Cardiovascular Events in Indonesian Patients with Coronary Artery Disease
Background: The polymorphism of cytochrome P450 2C19 (CYP2C19) has been documented as the determinant variability in the antiplatelet effect of clopidogrel. The relation between CYP2C19 polymorphism and the antiplatelet...